HOME >> BIOLOGY >> NEWS
Blocking blood vessels provides new option for large group of advanced lung cancer patients

ORLANDO, Fla. Patients with a particular type of advanced lung cancer may have a new option based on data presented here at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.

In fact, adding the "anti-angiogenesis inhibitor" bevacizumab (Avastin) to standard chemotherapy extended median survival beyond one year for the first time among patients with advanced non-small cell, non-squamous lung cancer, reported Alan Sandler, M.D., principal investigator of the multi-center study and director of Thoracic Oncology at the Vanderbilt-Ingram Cancer Center.

As a result of the study conducted through the Eastern Cooperative Oncology Group, ECOG recommends the regimen of bevacizumab plus the chemotherapies paclitaxel and carboplatin (PCB) as the new standard treatment for patients with this stage and type of lung cancer.

"These results show, for the first time, an improvement in survival with the addition of a targeted agent to standard chemotherapy in this patient population, and first time median survival has been extended beyond one year in advanced, non-small cell lung cancer," Sandler said.

The study enrolled 878 patients with advanced, non-squamous, non-small cell lung cancer between July 2001 and April 2004. Of those, 444 were randomly assigned to receive paclitaxel and carboplatin, considered the standard therapy, and 434 were assigned to receive the chemo combination plus bevacizumab.

Median survival the point at which half the patients enrolled in the study had died was 12.5 months for patients who received bevacizumab plus chemotherapy compared to 10.2 months for patients who received standard chemotherapy alone.

"We also observed improvements in patient benefit with the bevacizumab arm, including the time between enrollment and when tumors began growing again and the proportion o
'"/>

Contact: Cynthia Floyd Manley
cynthia.manley@vanderbilt.edu
615-430-8320
Vanderbilt University Medical Center
13-May-2005


Page: 1 2 3

Related biology news :

1. Blocking beta1-integrin to treat cancer
2. Blocking a premature aging syndrome with anticancer drugs
3. Blocking COX-1 slows tumor growth in mice
4. Blocking PLK-1 to beat bladder cancer
5. Blocking neurodegeneration by radiation and bone marrow transfer prevents inherited glaucoma in mice
6. Blocking cell signaling can stymie viral infections, study shows
7. Blocking cell suicide switch fails to stop prion damage in mouse brains
8. High blood pressure, low energy -- a recipe for heart failure
9. Brain blood flow gives clues to treating depression
10. Study finds gender differences in renal and other genes contributing to blood pressure
11. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/26/2019)... ... October 24, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today ... at the forthcoming American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 at ...
(Date:10/22/2019)... , ... October 21, 2019 , ... Join QPS ... Director of Bioanalytical in a live session on Thursday, October 31, 2019 ... partner. , A good CRO partner should have expertise in method development, which ...
(Date:10/17/2019)... ... 2019 , ... The scope of the quality system covers ... manufactures ready-to-use culture broth and buffers in its proprietary MediaBox™ format, bottles & ... This major step underpins the company’s philosophy of offering the highest quality equipment ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... ... , ... Diversified Technologies, Inc. has introduced a PEF production system ... improve processing. , The DTI Industrial PEF Unit can pre-treat whole pieces of fruits ... by up to 50% and achieve up to an 80% reduction of drying energy. ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... has received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. ... interface, the Fusion Bx 2.0 will give urologists across Europe the ability to ...
(Date:11/2/2019)... ... October 31, 2019 , ... Join Patrick Raber, ... live webinar on Friday, November 15, 2019 at 1pm EST to ... science of profiling T-cell receptors (TCRs) and B-cell receptors (BCRs), has been widely ...
(Date:10/30/2019)... ... October 30, 2019 , ... Western ... many roles innovation and technology play in educating the next generation of health ... learning opportunities and presentations by WesternU administrators and representatives of companies working with ...
Breaking Biology Technology:
Cached News: